Physician

Adedayo Odunsi, M.D

According to 2025 Medicare claims, Adedayo Odunsi, M.D (NPI: 1174501233) practices nephrology in the Dayton-Kettering-Beavercreek, OH market, with the plurality of this provider's patient population coming from Montgomery, OH. This provider's primary affiliated billing organization is RENAL PHYSICIANS INC (NPI: 1962486316; TIN: 310821503) and primary practice location at 45439-1648.

Odunsi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 353 traditional Medicare patients, billed 1,327 HCPCS/CPT codes, and received $130,330 in Medicare payments. The top billing code was 36902 (Insertion of needle and/or tube into hemodialysis circuit and balloon dilation of dialysis segment with review by radiologist). Part D data shows 781 prescription claims across 144 beneficiaries totaling $142,552 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 38 claims. Open Payments data shows 9 records totaling $159. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $658,293 to $130,330. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $107,213 and ending at $142,552. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	543	17,098	$658,293
2016	603	19,280	$683,571
2017	491	3,049	$338,871
2018	580	3,491	$446,821
2019	511	4,660	$336,744
2020	541	6,729	$349,409
2021	439	6,600	$281,041
2022	457	7,293	$301,922
2023	407	2,165	$144,145
2024	353	1,327	$130,330

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	65	599	$107,213
2016	86	824	$159,878
2017	93	1,099	$245,739
2018	102	924	$83,850
2019	97	648	$51,673
2020	125	690	$55,495
2021	116	754	$53,369
2022	146	803	$64,089
2023	125	736	$67,534
2024	144	781	$142,552

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	33	$9,144
2016	N/R	42	$6,841
2017	N/R	30	$1,814
2018	N/R	27	$4,198
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	38	$684

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
36902	Insertion of needle and/or tube into hemodialysis circuit and balloon dilation of dialysis segment with review by radiologist	99	116	$178
36215	Insertion of tube into chest or arm artery, each first order branch	50	54	$87
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	74	188	$59
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	51	85	$50
99152	Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes	130	165	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	17	521	$49,677
Farxiga	Dapagliflozin Propanediol	30	1,600	$29,463
Jardiance	Empagliflozin	14	1,020	$20,433
Kerendia	Finerenone	13	870	$17,916
Cinacalcet Hcl	Cinacalcet Hcl	13	966	$6,293

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	12	$391
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	14	$163
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	12	$130

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$159	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adedayo Odunsi, M.D?

Tedicare shows public-source Medicare data for Adedayo Odunsi, M.D (NPI 1174501233), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adedayo Odunsi, M.D have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adedayo Odunsi, M.D?

Adedayo Odunsi, M.D is linked to RENAL PHYSICIANS INC (billing NPI 1962486316) in the available physician profile data.

Does Adedayo Odunsi, M.D have Open Payments data?

Adedayo Odunsi, M.D has 9 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.